Literature DB >> 3104059

Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function.

J Braun, J R Kollert, J U Becker.   

Abstract

We have studied the pharmacokinetics of flecainide after the oral administration of 100 mg to 8 patients without renal impairment and 8 patients with mild to moderate renal failure. Both groups gave comparable results with respect to the peak plasma concentrations and the time to peak. There was a significant correlation between renal flecainide clearance and endogenous creatinine clearance. The elimination half-time in the patients with impaired renal function was significantly longer (19.9, SD 9.9 h) than that in the patients with normal renal function (11.5, SD 4.2 h), but the variability in the elimination half-time in renal failure could not be explained on the basis of the available results.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3104059     DOI: 10.1007/bf00541300

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  The influence of urinary pH on flecainide excretion and its serum pharmacokinetics.

Authors:  K A Muhiddin; A Johnston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

2.  Interaction of flecainide with digoxin and propranolol.

Authors:  G P Lewis; J L Holtzman
Journal:  Am J Cardiol       Date:  1984-02-27       Impact factor: 2.778

3.  Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide.

Authors:  H J Duff; D M Roden; R J Maffucci; B S Vesper; G J Conard; S B Higgins; J A Oates; R F Smith; R L Woosley
Journal:  Am J Cardiol       Date:  1981-12       Impact factor: 2.778

4.  Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients.

Authors:  G J Conard; G E Cronheim; H W Klempt
Journal:  Arzneimittelforschung       Date:  1982

5.  A comparison of the antiarrhythmic effects on AV junctional re-entrant tachycardia of oral and intravenous flecainide acetate.

Authors:  R S Bexton; K J Hellestrand; A W Nathan; R A Spurrell; A J Camm
Journal:  Eur Heart J       Date:  1983-02       Impact factor: 29.983

6.  Biotransformation and elimination of 14C-flecainide acetate in humans.

Authors:  R L McQuinn; G J Quarfoth; J D Johnson; E H Banitt; S V Pathre; S F Chang; R E Ober; G J Conard
Journal:  Drug Metab Dispos       Date:  1984 Jul-Aug       Impact factor: 3.922

7.  Oral flecainide for suppression of ventricular arrhythmias.

Authors:  G Vanhaleweyk; K Balakumaran; J Lubsen; J Roelandt; P G Hugenholtz
Journal:  Cardiology       Date:  1984       Impact factor: 1.869

Review 8.  Metabolism of flecainide.

Authors:  G J Conard; R E Ober
Journal:  Am J Cardiol       Date:  1984-02-27       Impact factor: 2.778

9.  Oral flecainide acetate for the treatment of ventricular arrhythmias.

Authors:  J L Anderson; J R Stewart; B A Perry; D D Van Hamersveld; T A Johnson; G J Conard; S F Chang; D C Kvam; B Pitt
Journal:  N Engl J Med       Date:  1981-08-27       Impact factor: 91.245

10.  [Determination of the concentration of a new antiarrhythmic, flecainide, in plasma using high pressure liquid chromatography (HPLC): sample preparation with extraction columns].

Authors:  J U Becker
Journal:  J Clin Chem Clin Biochem       Date:  1984-05
View more
  10 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH.

Authors:  A S Gross; G Mikus; C Fischer; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 4.  Safety of flecainide.

Authors:  Juan Tamargo; Alessandro Capucci; Philippe Mabo
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

5.  Failure of haemoperfusion to reduce flecainide intoxication. A case study.

Authors:  J Braun; J R Kollert; U Gessler; J U Becker
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Nov-Dec

Review 6.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

7.  Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.

Authors:  A S Gross; G Mikus; C Fischer; R Hertrampf; U Gundert-Remy; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

8.  Flecainide: evidence of non-linear kinetics.

Authors:  G Boriani; E Strocchi; A Capucci; R Callivà; L Frabetti; E Ambrosioni; B Magnani
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Primary and secondary detoxification in severe flecainide intoxication.

Authors:  D Götz; S Pohle; D Barckow
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 10.  Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide.

Authors:  Juan Tamargo; Jean-Yves Le Heuzey; Phillipe Mabo
Journal:  Eur J Clin Pharmacol       Date:  2015-04-15       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.